A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value.
A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value. Focusing on non-small cell lung cancer (NSCLC), the brief used the IVI-NSCLC model, an open-source simulation model that assesses the costs, benefits, and risks of sequences of treatment for EGFR-mutated disease. The model also includes an experimental module for calculating the value of hope, which has been suggested as one of the elements to augment conventional cost-effectiveness analysis.
Costs and outcomes for 2 possible treatment sequences were determined and the value of hope was added to the quality-adjusted life years (QALYs) by estimating the QALYs a patient would need to obtain to be indifferent toward the 2 sequences of treatment.
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
AMGA Releases Population Health Framework to Improve ASCVD Secondary Prevention
June 18th 2025Proven interventions to improve care, address disparities, and support lipid management are woven throughout AMGA Foundation's new framework to guide population health–based secondary prevention strategies for atherosclerotic cardiovascular disease (ASCVD).
Read More